Core Viewpoint - *ST Lvkang (002868.SZ) expects a net profit attributable to shareholders of the listed company to be between -140 million and -125 million yuan for 2025, with operating revenue projected to be between 500 million and 515 million yuan [1] Group 1: Financial Performance - The main reason for the company's performance change this year is the expected positive equity attributable to shareholders due to the divestiture of the severely loss-making photovoltaic film business in 2025, which will no longer be included in the consolidated financial statements [1] - The net profit attributable to shareholders is still expected to be a loss primarily due to the losses incurred by the photovoltaic film business before its divestiture, which accounted for over 90% of the losses [1] - The veterinary medicine business has seen revenue growth this year, mainly driven by higher-margin products and an optimized product structure, resulting in an overall improvement in gross margin compared to 2024 [1]

格隆汇1月27日丨*ST绿康(002868.SZ)公布，预计2025年归属于上市公司股东的净利润-14,000万元 ～-12,500万元，扣除非经常性损益后的净利润-14,000万元～-12,900万元，营业收入50,000万元～51,500 万元。 公司本年业绩变动的主要原因是：1、公司本年归属于上市公司股东的所有者权益转正主要原因系2025 年将亏损严重的光伏胶膜业务剥离，剥离后光伏胶膜子公司不再纳入上市公司合并报表范围。2、本年 归属于上市公司股东的净利润仍为亏损主要系由光伏胶膜业务在剥离前的亏损导致，光伏胶膜子公司的 亏损占比在90%以上。3、本年兽药业务收入有所增长，增长部份主要来源于毛利较高产品，加上产品 结构的优化，整体毛利率水平较2024年有所提升。 ...

Core Viewpoint - The company has successfully passed the veterinary drug GMP acceptance and obtained the Veterinary Drug GMP Certificate and Production License, indicating an expansion in its production capabilities and product range in the vaccine and biological products sector [1][2]. Group 1: GMP Certificate and Production License - The company’s Lanzhou branch has received the Veterinary Drug GMP Certificate, which covers the production of various vaccines including inactivated vaccines for foot-and-mouth disease and live vaccines [1]. - The effective period for both the GMP Certificate and the Production License is from January 14, 2026, to January 13, 2031 [1]. Group 2: Production Capabilities and Product Development - The newly approved production lines for cell suspension culture live vaccines and bacterial live vaccines will be utilized for producing vaccines such as the live vaccine for pseudorabies in pigs and the live vaccine for piglet paratyphoid [1]. - The company is in the process of applying for the veterinary product approval numbers for the pseudorabies live vaccine and the piglet paratyphoid live vaccine to expedite their market launch [1]. - The acquisition of the GMP Certificate and Production License signifies that the production lines meet the regulatory requirements, enhancing the company’s core competitiveness and profitability by diversifying its product offerings [2].

Summary of the Conference Call for 瑞普生物 (Reap Bio) Company Overview - 瑞普生物 is engaged in the animal health industry, focusing on poultry products, vaccines, and pet care products. The company has shown resilience in its poultry segment and is optimizing its product structure with an increasing share of vaccine business [2][3]. Key Points Industry and Business Performance - The poultry products business remains the core driver of performance, with a significant contribution to overall revenue [2][3]. - Vaccine business has shifted from a 50:50 ratio with pharmaceuticals to a 60:40 ratio, indicating a substantial increase in vaccine sales [3]. - The pet care segment achieved record sales, nearing 1 billion yuan in 2025, marking the highest level in the company's history [3]. - The company has made breakthroughs in research and development, particularly in subunit vaccines and mRNA vaccines, with plans to launch industry-leading products [2][3]. Financial Performance and Challenges - In Q4 2025, the downturn in the pig farming sector exerted pressure on the company's continued use of formulations, but the poultry segment's profitability and emerging pet business mitigated the overall impact [2][4]. - The raw material drug business underperformed expectations, particularly with the price of florfenicol experiencing a downturn. The company plans to focus on high-margin products and optimize production capacity [2][5]. Strategic Initiatives - The company is enhancing its service model by providing comprehensive lifecycle services to major clients, which has helped maintain profitability despite market challenges [4]. - Plans to expand the customer base in the supply chain business to 20,000 pet hospitals and stores by 2028, aiming for total sales exceeding 2 billion yuan [3][8]. - The company is also pursuing international market expansion, with a goal for export revenue to account for at least 10% of total income in the next 3-5 years [11]. Product Development and Market Position - The cat trivalent vaccine is a core product in the pet segment, accounting for 30%-40% of sales, with plans for market share expansion through channel promotion and brand enhancement [6][7]. - The company is actively engaging with large-scale breeding and food processing enterprises to ensure stable growth in synthetic biology projects, particularly in the silk protein project, which has significant market potential [12]. Future Outlook - The company anticipates continued growth in the pet segment, with strong performance expected in Q4 2026, particularly during promotional events like Double Eleven [5]. - The overall strategy includes optimizing product structure and enhancing operational efficiency to sustain revenue and profit growth [3][4]. Miscellaneous - Non-operating income for Q4 is expected to be around 100 million yuan, primarily from government subsidies and investment income [10]. - The company is in the process of listing with 瑞派 (Ruipai) and has submitted necessary documentation to the Hong Kong Stock Exchange [9]. This summary encapsulates the key insights from the conference call, highlighting the company's performance, strategic initiatives, and future outlook in the animal health industry.

Core Viewpoint - The article highlights the dedication and achievements of Du Jihong, a key figure in the veterinary drug quality and animal product safety monitoring in Beijing, emphasizing her role in ensuring food safety and regulatory compliance in the livestock industry [3][4][8]. Group 1: Monitoring and Regulatory Achievements - Du Jihong has been instrumental in leading veterinary drug monitoring efforts, overseeing the inspection of 151 veterinary drug products across 66 enterprises and farms, which has contributed to a high compliance rate in Beijing [4][5]. - Under her leadership, a total of 230 monitoring subjects were tested nearly 4,000 times, successfully identifying illegal additives in veterinary drugs [4][5]. - The establishment of a "1+4+5" tiered monitoring system has allowed for precise management of 18 large-scale breeding enterprises, significantly enhancing the efficiency and accuracy of bacterial resistance monitoring [5][6]. Group 2: Event Support and Emergency Preparedness - During the Beijing 2022 Winter Olympics, Du Jihong led the livestock product safety team, implementing a comprehensive monitoring mechanism that ensured zero errors in product safety during the event [6][7]. - She developed detailed testing plans and sampling protocols, conducting over 20 sampling surveys and completing 386 batches of livestock product tests [6][7]. Group 3: Training and Capacity Building - Du Jihong has organized over 5,000 training sessions for industry professionals, significantly improving the overall monitoring capabilities within the sector [6][7]. - Her efforts in training have led to notable achievements in national skill competitions, showcasing the enhanced skills of participants [6][7]. Group 4: Safety and Risk Management - A strong emphasis on safety has been a hallmark of Du Jihong's work, with the implementation of a three-tier inspection mechanism and the establishment of safety management protocols, resulting in zero accidents at the monitoring center [7][8]. - The proactive approach to safety includes distributing safety manuals and conducting on-site safety checks, contributing to a culture of safety within the veterinary drug industry [7][8].

Core Viewpoint - The approval of a new veterinary drug, a trivalent inactivated vaccine for Newcastle disease, avian influenza (H9 subtype), and infectious bursal disease, represents a significant advancement for the poultry industry, addressing critical diseases that cause substantial economic losses [1] Company Summary - The company,普莱柯 (603566.SH), announced the approval of its wholly-owned subsidiary, 洛阳惠中生物技术有限公司, for a new veterinary drug [1] - The new vaccine is officially registered as of January 12, 2026, under the Ministry of Agriculture and Rural Affairs of the People's Republic of China [1] Industry Summary - Newcastle disease, avian influenza (H9 subtype), and infectious bursal disease are major infectious diseases that severely impact the poultry industry, leading to significant economic losses [1] - The new trivalent inactivated vaccine offers several advantages: 1. Utilizes suspension cell culture technology for more controllable and efficient production [1] 2. Achieves high soluble expression of VP2 protein for infectious bursal disease in a baculovirus vector [1] 3. Provides immunity lasting over 4 months and allows for multi-disease prevention with a single injection, reducing stress on chicken populations from frequent vaccinations [1]

Core Viewpoint - The company has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug, which will enhance its product offerings in the poultry vaccine market [1] Group 1: Product Development - The new veterinary drug is a trivalent inactivated vaccine for preventing Newcastle disease, H9 subtype avian influenza, and infectious bursal disease [1] - The vaccine is characterized by efficient production, high expression, and long-lasting immunity [1] Group 2: Market Impact - The approval of the new veterinary drug certificate will enrich the company's poultry vaccine product line and improve its competitive edge in the market [1]

Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Luoyang Huizhong Biotechnology Co., Ltd., has received a new veterinary drug registration certificate for a trivalent inactivated vaccine targeting three chicken diseases, enhancing the company's product portfolio and competitiveness in the poultry vaccine market [1] Group 1 - The vaccine is designed to prevent three diseases: Newcastle disease, avian influenza (H9 subtype), and infectious bursal disease [1] - The registration certificate was issued by the Ministry of Agriculture and Rural Affairs on January 12, 2026, marking a significant regulatory milestone for the product [1] - The vaccine is classified as a Category III new veterinary drug, indicating its potential impact on animal health and the poultry industry [1] Group 2 - The product still requires approval for veterinary drug product registration before it can be marketed, indicating further steps in the regulatory process [1] - This development enriches the company's poultry vaccine offerings, which is expected to enhance its competitive edge in the market [1]

Core Viewpoint - The company expects its net profit attributable to shareholders to be between 235 million to 271 million yuan for the year 2025 [2] Group 1 - The company announced its profit forecast for 2025 [2] - The expected net profit range indicates a positive outlook for the company's financial performance [2]

Core Viewpoint - The company expects a significant turnaround in net profit for 2025, projecting a net profit attributable to shareholders of 235 million to 271 million yuan, indicating a year-on-year recovery from losses [1] Group 1: Financial Performance - The company reported a substantial increase in net profit compared to the same period last year, driven by revenue growth from both domestic and international markets [1] - The expected net profit, excluding non-recurring gains and losses, is projected to be between 212.5 million and 248.5 million yuan, also reflecting a year-on-year recovery [1] - The reduction in financial expenses is attributed to the early redemption of convertible bonds, contributing positively to the overall financial performance [1] Group 2: Revenue Drivers - The increase in net profit is primarily due to enhanced revenue, which was supported by technological innovation, improved utilization rates of formulations and active pharmaceutical ingredients, and rising prices of raw materials [1] - The company anticipates that non-recurring gains and losses will impact net profit by approximately 22.5 million yuan during the reporting period [1]